MPM Oncology Impact Management »

Cartesian Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Cartesian Therapeutics (RNAC) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Cartesian Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Cartesian Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cartesian Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $7.0M 260k 27.01

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Cartesian Therapeutics

BlackRock
Jpmorgan Chase & Co
Artal Group
MPM Oncology Impact Management
Ikarian Capital
Vanguard Group
State Street Corporation
Geode Capital Management
Logos Global Management
Nuveen Asset Management
Marshall Wace
Sphera Funds Management
Delphi Financial
Bank of New York Mellon
Charles Schwab Investment Management

View all funds holding Cartesian Therapeutics